Bausch Health Companies (TSE:BHC) Shares Down 3.8% – Here’s What Happened

Posted by Tyrone Williams on Sep 11th, 2026

Bausch Health Companies Inc. (TSE:BHC – Get Free Report) fell 3.8% during mid-day trading on Friday . The company traded as low as C$8.09 and last traded at C$8.10. Approximately 665,687 shares changed hands during mid-day trading, an increase of 22% from the average daily volume of 545,133 shares. The stock had previously closed at C$8.42.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 22nd. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Get Our Latest Stock Report on BHC

Bausch Health Companies Stock Performance

The firm has a market cap of C$3.03 billion, a price-to-earnings ratio of -2.76, a price-to-earnings-growth ratio of 0.21 and a beta of 0.71. The company has a quick ratio of 0.58, a current ratio of 1.44 and a debt-to-equity ratio of -1,173.29. The stock has a fifty day moving average price of C$8.13 and a 200-day moving average price of C$7.65.

Bausch Health Companies (TSE:BHC – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%.The firm had revenue of C$4.05 billion during the quarter. On average, analysts expect that Bausch Health Companies Inc. will post 5.5472637 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.